RegeneRx Completes Patient Enrollment of First Phase II Clinical Trial of Topical Drug Candidate RGN-137
22-Aug-2008 -
RegeneRx Biopharmaceuticals, Inc. announced that it completed enrollment of its first of four ongoing Phase II clinical trials. The trial is a double-blind, placebo-controlled, dose-escalating clinical trial evaluating the safety and efficacy of the Company’s topical drug candidate, RGN-137, in ...
clinical trials
pressure
regulatory affairs
+1